← GIP/GLP-1 & amylin agonists × glycemic control

SynthesisScientific reports2025

Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis.

Xiaoyu Ren et al.PubMed ↗Full text ↗Publisher ↗

  • Tirzepatideno clear effectLower HbA1-c, no range given, lower fasting blood sugar, no range given, lower body weight, no range given.No ranges given.
  • Semaglutideno clear effectLower HbA1-c, no range given, lower fasting blood sugar, no range given, lower body weight, no range given.No ranges given.
  • Liraglutideno clear effectLower HbA1-c, no range given, lower fasting blood sugar, no range given, lower body weight, no range given.No ranges given.

What the trial testedas reported · 25,572 people · 2025

No range given

Reported lower HbA1-c, no range given

−2.30percentage points

tirzepatide vs placebo

As reported

difference −2.3 %, no interval

No range given

Reported lower fasting blood sugar, no range given

−3.10mmol/L

tirzepatide vs placebo

As reported

difference −3.1 mmol/L, no interval · the paper's word: FPG

No range given

Reported lower HbA1-c, no range given

−1.50percentage points

semaglutide vs placebo

As reported

difference −1.5 %, no interval

No range given

Reported lower fasting blood sugar, no range given

−2.00mmol/L

semaglutide vs placebo

As reported

difference −2 mmol/L, no interval · the paper's word: FPG

+5 more in the walkthrough ↓

Who was studied, and how

25,572people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

tirzepatide
placebo

Reported lower HbA1-c, no range given−2.30

Reported lower fasting blood sugar, no range given−3.10

randomised

The trial randomly assignedassigned by chance

semaglutide
placebo

Reported lower HbA1-c, no range given−1.50

Reported lower fasting blood sugar, no range given−2.00

randomised

the abstract, start to end

… the greatest reduction in HbA1-c (MD: -2.3%) and FPG (MD: -3.1mmol/L); semaglutide was second (HbA1-c: MD: -1.5%; FPG: MD: -2mmol/L); liraglutide was third (HbA1-c: MD: -1.2% FPG: MD: -1.6mmol/L) (P<0.05).

Tirzepatide (MD: -9.1 kg), semaglutide (MD: -2.8 kg) and liraglutide (MD: -1.2 kg) (P<0.05) had significant …

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
HbA1-ctirzepatide vs placebo
−2.3
FPGtirzepatide vs placebo
−3.1
HbA1-csemaglutide vs placebo
−1.5
FPGsemaglutide vs placebo
−2
HbA1-cliraglutide vs placebo
−1.2
FPGliraglutide vs placebo
−1.6
Body weighttirzepatide vs placebo
−9.1
Body weightsemaglutide vs placebo
−2.8
Body weightliraglutide vs placebo
−1.2
GLP-1 receptor agonistsGIP/GLP-1 & amylin agonistsGlycemic controlBody weight & composition
1 / 4

14 papers cite it

2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 40619508